MODERNA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 132.9 USD | +0.17% |
|
+13.29% | +33.63% |
| May. 17 | Moderna Insider Sold Shares Worth $1,912,350, According to a Recent SEC Filing | MT |
| May. 17 | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
ETFs positioned on Moderna, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.20% | 17 M€ | +5.25% | - | |
| 0.20% | 330 M€ | -.--% | ||
| 0.19% | 6 M€ | +17.98% | - | |
| 0.18% | 121 M€ | +8.42% | - | |
| 0.17% | 1 M€ | -.--% | - | |
| 0.17% | 744 M€ | +9.63% | ||
| 0.17% | 8 M€ | +7.30% | - | |
| 0.16% | 26 M€ | +21.70% | - | |
| 0.16% | 9 M€ | +10.44% | ||
| 0.15% | 50 M€ | +10.93% | ||
| 0.15% | 2,517 M€ | +13.12% | - | |
| 0.14% | 559 M€ | +14.30% | ||
| 0.14% | 1,848 M€ | +18.39% | - | |
| 0.13% | 35 M€ | +9.13% | - | |
| 0.12% | 57 M€ | +22.09% | - | |
| 0.11% | 273 M€ | -.--% | ||
| 0.11% | 655 M€ | -.--% | - | |
| 0.11% | 1,174 M€ | +23.54% | ||
| 0.11% | 9 M€ | +11.05% | - | |
| 0.11% | 1 M€ | -.--% | ||
| 0.10% | 283 M€ | +20.97% | ||
| 0.09% | 34 M€ | +12.61% | - | |
| 0.09% | 104 M€ | +10.57% |
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
2024-05-31
- Bernstein Strategic Decisions Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
132.9
USD
Average target price
138.5
USD
Spread / Average Target
+4.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +33.63% | 50.93B | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +24.73% | 12.17B | |
| +28.31% | 12.16B | |
| -6.26% | 11.42B |
- Stock Market
- Equities
- MRNA Stock
- Funds and ETFs Moderna, Inc.
